The North America Fibromyalgia Treatment Market should witness market growth of 3.7% CAGR during the forecast period (2023-2030).
The complexity of fibromyalgia is the reason why diagnosis and treatment are required to take a multifaceted approach, combining medical practitioners from different specialties to address the disease's many symptoms and comorbidities. In addition to several drugs, it may also be treated with dietary and lifestyle changes. The symptoms of fibromyalgia include extreme pain, difficulty sleeping, tiredness, irritability, and memory loss. Fibromyalgia is commonly accompanied by several other symptoms as well. Only three drugs have been approved for use, particularly in treating fibromyalgia, at this time.
Because of this, products that are off-label are utilized more frequently. But increased research and development in pain management is anticipated to support using approved medications for the illness indication. The burden of chronic pain is mostly to blame for the market's expansion. Researchers have found that fibromyalgia changes how the brain and spinal cord process painful and non-painful signals, increasing the intensity of painful sensations. The increased incidence of chronic pain conditions like fibromyalgia is anticipated to increase demand for different treatment alternatives, ultimately fueling market expansion during the anticipated period.
Mexico's road traffic fatalities have remained consistently high in recent years, despite the country's population of nearly 130 million people. There were over 16,000 recorded deaths in 2019. Due to a lack of accountability among various sectors and institutions, Mexico's federal government struggled to achieve intersectoral coordination and progress in road safety, resulting in fatal and non-fatal traffic injuries. The increasing number of road accidents in the region will create growth opportunities for the market as FM can occur to people involved in road accidents, thereby boosting the market expansion in the region.
The US market dominated the North America Fibromyalgia Treatment Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,022.1 million by 2030. The Canada market is poised to grow at a CAGR of 6.1% during (2023-2030). Additionally, The Mexico market should witness a CAGR of 5.1% during (2023-2030).
Based on Drug Class, the market is segmented into Anticonvulsants, Antidepressants, Muscle Relaxants and Others. Based on Distribution Channel, the market is segmented into Drug stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Novartis AG, Eli Lilly And Company, Amneal Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, Abbott Laboratories, Viatris, Inc., and Sun Pharmaceutical Industries Ltd.
The complexity of fibromyalgia is the reason why diagnosis and treatment are required to take a multifaceted approach, combining medical practitioners from different specialties to address the disease's many symptoms and comorbidities. In addition to several drugs, it may also be treated with dietary and lifestyle changes. The symptoms of fibromyalgia include extreme pain, difficulty sleeping, tiredness, irritability, and memory loss. Fibromyalgia is commonly accompanied by several other symptoms as well. Only three drugs have been approved for use, particularly in treating fibromyalgia, at this time.
Because of this, products that are off-label are utilized more frequently. But increased research and development in pain management is anticipated to support using approved medications for the illness indication. The burden of chronic pain is mostly to blame for the market's expansion. Researchers have found that fibromyalgia changes how the brain and spinal cord process painful and non-painful signals, increasing the intensity of painful sensations. The increased incidence of chronic pain conditions like fibromyalgia is anticipated to increase demand for different treatment alternatives, ultimately fueling market expansion during the anticipated period.
Mexico's road traffic fatalities have remained consistently high in recent years, despite the country's population of nearly 130 million people. There were over 16,000 recorded deaths in 2019. Due to a lack of accountability among various sectors and institutions, Mexico's federal government struggled to achieve intersectoral coordination and progress in road safety, resulting in fatal and non-fatal traffic injuries. The increasing number of road accidents in the region will create growth opportunities for the market as FM can occur to people involved in road accidents, thereby boosting the market expansion in the region.
The US market dominated the North America Fibromyalgia Treatment Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,022.1 million by 2030. The Canada market is poised to grow at a CAGR of 6.1% during (2023-2030). Additionally, The Mexico market should witness a CAGR of 5.1% during (2023-2030).
Based on Drug Class, the market is segmented into Anticonvulsants, Antidepressants, Muscle Relaxants and Others. Based on Distribution Channel, the market is segmented into Drug stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Novartis AG, Eli Lilly And Company, Amneal Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, Abbott Laboratories, Viatris, Inc., and Sun Pharmaceutical Industries Ltd.
Scope of the Study
By Drug Class
- Anticonvulsants
- Antidepressants
- Muscle Relaxants
- Others
By Distribution Channel
- Drug stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- AbbVie, Inc.
- Novartis AG
- Eli Lilly And Company
- Amneal Pharmaceuticals, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Zydus Lifesciences Ltd.
- Lupin Limited
- Abbott Laboratories
- Viatris, Inc.
- Sun Pharmaceutical Industries Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Fibromyalgia Treatment Market by Drug Class
Chapter 4. North America Fibromyalgia Treatment Market by Distribution Channel
Chapter 5. North America Fibromyalgia Treatment Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- AbbVie, Inc.
- Novartis AG
- Eli Lilly And Company
- Amneal Pharmaceuticals, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Zydus Lifesciences Ltd.
- Lupin Limited
- Abbott Laboratories
- Viatris, Inc.
- Sun Pharmaceutical Industries Ltd.
Methodology
LOADING...
